Ocular manifestations of graft-versus-host disease

10 years’ experience

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: To evaluate the ocular presentation, treatment, and clinical course of graft-versus-host disease (GVHD). Design: Retrospective case series. Participants: Two hundred and forty-nine patients with systemic GVHD were included in the study. Methods: Ocular and systemic data were collected from 2003 to 2013. Main outcome measures: Mortality, visual acuity, and response of ocular symptoms. Results: Sixty-four patients had ocular manifestations (25.7%). At presentation, the mean age was 44.5 years and mean latency was 16.4 months. The most common presentations were keratoconjunctivitis sicca, cataract, blepharitis, ocular hypertension, and flamentary keratitis. Visual acuity at presentation was 20/49; at the worst point in the disease was 20/115; and at most recent visit was 20/63. When topical anti-infammatory drops were used in addition to tears, 54.3% of patients’ ocular symptoms stabilized. When autologous serum was used in addition, 80% stabilized. The overall 10-year mortality of GVHD was 29.7%. For those with ocular involvement, it was 21.9%. Conclusion: Systemic GVHD has a high mortality rate, but ocular involvement does not suggest a worse prognosis. The main ocular presentations were keratoconjunctivitis sicca, cataracts, and ocular hypertension. Dry eyes in this population were very severe with overall worsening in visual acuity. However, with a step-wise approach involving topical anti-infammatory medications and autologous serum tears, ocular symptoms do improve. It is important to monitor these patients closely, as they are prone to serious ocular complications such as corneal perforation and endophthalmitis.

Original languageEnglish (US)
Pages (from-to)1209-1213
Number of pages5
JournalClinical Ophthalmology
Volume9
DOIs
StatePublished - Jul 3 2015

Fingerprint

Eye Manifestations
Graft vs Host Disease
Keratoconjunctivitis Sicca
Visual Acuity
Ocular Hypertension
Cataract
Mortality
Corneal Perforation
Blepharitis
Endophthalmitis
Keratitis
Serum
Tears

Keywords

  • Corneal ulceration
  • Dry eye
  • Keratitis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ocular manifestations of graft-versus-host disease : 10 years’ experience. / Lin, Xihui; Cavanagh, Harrison D.

In: Clinical Ophthalmology, Vol. 9, 03.07.2015, p. 1209-1213.

Research output: Contribution to journalArticle

@article{097a5ed393314d22baa18f2016a81a28,
title = "Ocular manifestations of graft-versus-host disease: 10 years’ experience",
abstract = "Purpose: To evaluate the ocular presentation, treatment, and clinical course of graft-versus-host disease (GVHD). Design: Retrospective case series. Participants: Two hundred and forty-nine patients with systemic GVHD were included in the study. Methods: Ocular and systemic data were collected from 2003 to 2013. Main outcome measures: Mortality, visual acuity, and response of ocular symptoms. Results: Sixty-four patients had ocular manifestations (25.7{\%}). At presentation, the mean age was 44.5 years and mean latency was 16.4 months. The most common presentations were keratoconjunctivitis sicca, cataract, blepharitis, ocular hypertension, and flamentary keratitis. Visual acuity at presentation was 20/49; at the worst point in the disease was 20/115; and at most recent visit was 20/63. When topical anti-infammatory drops were used in addition to tears, 54.3{\%} of patients’ ocular symptoms stabilized. When autologous serum was used in addition, 80{\%} stabilized. The overall 10-year mortality of GVHD was 29.7{\%}. For those with ocular involvement, it was 21.9{\%}. Conclusion: Systemic GVHD has a high mortality rate, but ocular involvement does not suggest a worse prognosis. The main ocular presentations were keratoconjunctivitis sicca, cataracts, and ocular hypertension. Dry eyes in this population were very severe with overall worsening in visual acuity. However, with a step-wise approach involving topical anti-infammatory medications and autologous serum tears, ocular symptoms do improve. It is important to monitor these patients closely, as they are prone to serious ocular complications such as corneal perforation and endophthalmitis.",
keywords = "Corneal ulceration, Dry eye, Keratitis",
author = "Xihui Lin and Cavanagh, {Harrison D}",
year = "2015",
month = "7",
day = "3",
doi = "10.2147/OPTH.S84704",
language = "English (US)",
volume = "9",
pages = "1209--1213",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Ocular manifestations of graft-versus-host disease

T2 - 10 years’ experience

AU - Lin, Xihui

AU - Cavanagh, Harrison D

PY - 2015/7/3

Y1 - 2015/7/3

N2 - Purpose: To evaluate the ocular presentation, treatment, and clinical course of graft-versus-host disease (GVHD). Design: Retrospective case series. Participants: Two hundred and forty-nine patients with systemic GVHD were included in the study. Methods: Ocular and systemic data were collected from 2003 to 2013. Main outcome measures: Mortality, visual acuity, and response of ocular symptoms. Results: Sixty-four patients had ocular manifestations (25.7%). At presentation, the mean age was 44.5 years and mean latency was 16.4 months. The most common presentations were keratoconjunctivitis sicca, cataract, blepharitis, ocular hypertension, and flamentary keratitis. Visual acuity at presentation was 20/49; at the worst point in the disease was 20/115; and at most recent visit was 20/63. When topical anti-infammatory drops were used in addition to tears, 54.3% of patients’ ocular symptoms stabilized. When autologous serum was used in addition, 80% stabilized. The overall 10-year mortality of GVHD was 29.7%. For those with ocular involvement, it was 21.9%. Conclusion: Systemic GVHD has a high mortality rate, but ocular involvement does not suggest a worse prognosis. The main ocular presentations were keratoconjunctivitis sicca, cataracts, and ocular hypertension. Dry eyes in this population were very severe with overall worsening in visual acuity. However, with a step-wise approach involving topical anti-infammatory medications and autologous serum tears, ocular symptoms do improve. It is important to monitor these patients closely, as they are prone to serious ocular complications such as corneal perforation and endophthalmitis.

AB - Purpose: To evaluate the ocular presentation, treatment, and clinical course of graft-versus-host disease (GVHD). Design: Retrospective case series. Participants: Two hundred and forty-nine patients with systemic GVHD were included in the study. Methods: Ocular and systemic data were collected from 2003 to 2013. Main outcome measures: Mortality, visual acuity, and response of ocular symptoms. Results: Sixty-four patients had ocular manifestations (25.7%). At presentation, the mean age was 44.5 years and mean latency was 16.4 months. The most common presentations were keratoconjunctivitis sicca, cataract, blepharitis, ocular hypertension, and flamentary keratitis. Visual acuity at presentation was 20/49; at the worst point in the disease was 20/115; and at most recent visit was 20/63. When topical anti-infammatory drops were used in addition to tears, 54.3% of patients’ ocular symptoms stabilized. When autologous serum was used in addition, 80% stabilized. The overall 10-year mortality of GVHD was 29.7%. For those with ocular involvement, it was 21.9%. Conclusion: Systemic GVHD has a high mortality rate, but ocular involvement does not suggest a worse prognosis. The main ocular presentations were keratoconjunctivitis sicca, cataracts, and ocular hypertension. Dry eyes in this population were very severe with overall worsening in visual acuity. However, with a step-wise approach involving topical anti-infammatory medications and autologous serum tears, ocular symptoms do improve. It is important to monitor these patients closely, as they are prone to serious ocular complications such as corneal perforation and endophthalmitis.

KW - Corneal ulceration

KW - Dry eye

KW - Keratitis

UR - http://www.scopus.com/inward/record.url?scp=84936853856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936853856&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S84704

DO - 10.2147/OPTH.S84704

M3 - Article

VL - 9

SP - 1209

EP - 1213

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -